Evidence map›Paper›PMID 30894657›Full record

ArticleScientific reports2019

Oligomeric self-association contributes to E2A-PBX1-mediated oncogenesis.

Chiou-Hong Lin, Zhong Wang, Jesús Duque-Afonso, Stephen Hon-Kit Wong, Janos Demeter, Alexander V Loktev, Tim C P Somervaille, Peter K Jackson, Michael L Cleary

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. PBX1: a TALE of two seasons-key roles during development and in cancer.Frontiers in cell and developmental biology · 2024
    Review
  3. Comprehensive summary: the role of PBX1 in development and cancers.Frontiers in cell and developmental biology · 2024
    Review
  4. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Chiou-Hong LinDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Zhong WangDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Jesús Duque-AfonsoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Stephen Hon-Kit WongDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Janos DemeterBaxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Alexander V LoktevBaxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Tim C P SomervailleDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Peter K JacksonBaxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Michael L ClearyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA. mcleary@stanford.edu.
Stanford University · USBaxter (United States) · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Spectrum Stanford Center for clinical and Translational Research and EducationKL2TR001083 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$4.9M
Functional and Translational Epigenomics of Acute Lymphoblastic LeukemiaR01CA214888 · NCI · STANFORD UNIVERSITY · PI CLEARY, MICHAEL L · 2018 to 2023
$1.8M
Cancer Research UK 29389NCATS NIH HHS KL2 TR001083NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR003142NCI NIH HHS P30 CA124435NCI NIH HHS R01 CA214888
6 · The paper itself

Abstract

The PBX1 homeodomain transcription factor is converted by t(1;19) chromosomal translocations in acute leukemia into the chimeric E2A-PBX1 oncoprotein. Fusion with E2A confers potent transcriptional activation and constitutive nuclear localization, bypassing the need for dimerization with protein partners that normally stabilize and regulate import of PBX1 into the nucleus, but the mechanisms underlying its oncogenic activation are incompletely defined. We demonstrate here that E2A-PBX1 self-associates through the PBX1 PBC-B domain of the chimeric protein to form higher-order oligomers in t(1;19) human leukemia cells, and that this property is required for oncogenic activity. Structural and functional studies indicate that self-association facilitates the binding of E2A-PBX1 to DNA. Mutants unable to self-associate are transformation defective, however their oncogenic activity is rescued by the synthetic oligomerization domain of FKBP, which confers conditional transformation properties on E2A-PBX1. In contrast to self-association, PBX1 protein domains that mediate interactions with HOX DNA-binding partners are dispensable. These studies suggest that oligomeric self-association may compensate for the inability of monomeric E2A-PBX1 to stably bind DNA and circumvents protein interactions that otherwise modulate PBX1 stability, nuclear localization, DNA binding, and transcriptional activity. The unique dependence on self-association for E2A-PBX1 oncogenic activity suggests potential approaches for mechanism-based targeted therapies.

Indexed as

Gene Expression Regulation, NeoplasticBasic Helix-Loop-Helix ProteinsCarcinogenesisCell Line, TumorChromosomes, Human, Pair 1Chromosomes, Human, Pair 19DNA, NeoplasmHEK293 CellsHumansLeukemia, Myeloid, AcuteOncogene Proteins, FusionPre-B-Cell Leukemia Transcription Factor 1Protein BindingProtein MultimerizationProtein StabilityTacrolimus Binding ProteinsBasic Helix-Loop-Helix ProteinsDNA, NeoplasmOncogene Proteins, FusionPBX1 protein, humanPre-B-Cell Leukemia Transcription Factor 1Tacrolimus Binding ProteinsTCF3 protein, human

Identifiers

PMID30894657
PMCPMC6426973
OpenAlexW2924527411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.